Intravenous Immunoglobulins (IVIG) Market is poised for steady expansion due to rising incidences of immune disorders, increasing geriatric population, and growing demand for effective immunotherapy. Intravenous immunoglobulins are blood products used to treat various autoimmune, infectious, and idiopathic diseases by boosting immune responses. With advancements in plasma fractionation technologies and improved healthcare infrastructure, the IVIG market is projected to witness significant growth over the coming years.

The intravenous immunoglobulins market was valued at USD 17.00 billion in 2024 and is expected to grow from USD 18.40 billion in 2025 to USD 33.81 billion by 2032, reflecting a compound annual growth rate (CAGR) of 9.1% during the 2025–2032 period. North America led the market in 2024, accounting for a 57.09% share.

Top Companies in the Market

• Shire (Takeda Pharmaceutical Company Limited)
• CSL Behring
• Grifols, S.A.
• Kedrion S.p.A
• Octapharma
• Bio Products Laboratory Ltd.
• Biotest AG
• China Biologic Products Holdings, Inc.
• LFB SA
• Shanghai RAAS Blood Products Co., Ltd.

Market Drivers and Trends

Key drivers of the IVIG market include:

• Rising prevalence of immunodeficiency disorders such as primary immunodeficiency (PI), chronic inflammatory demyelinating polyneuropathy (CIDP), and Kawasaki disease.

• Growing geriatric population globally, which is more susceptible to immune-related diseases.

• Increased awareness and diagnosis of rare and chronic autoimmune conditions.

• Expansion of therapeutic indications for IVIG, including off-label uses in neurology and hematology.

Advancements in plasma fractionation technology and improved logistics in plasma collection have also contributed to increased production efficiency and supply chain robustness.

Key Industry Development

In May 2019, the U.S. Food and Drug Administration (FDA) approved a Prior Approval Supplement (PAS) for ADMA Biologics, Inc.’s immunoglobulin product BIVIGAM. Following the approval, ADMA commenced commercial sales of the product, marking a significant milestone in expanding treatment availability for patients with immune deficiencies.

Market Drivers & Restraints

Market Drivers:

• Increasing prevalence of primary immunodeficiency diseases and autoimmune disorders.
• Rising use of IVIG therapies for off-label conditions such as chronic inflammatory demyelinating polyneuropathy (CIDP) and myasthenia gravis.
• Growing elderly population prone to immune-related illnesses.
• Expansion of healthcare infrastructure and patient access to immunoglobulin therapies.

Market Restraints:

• High cost associated with IVIG therapies, limiting accessibility in low-income regions.
• Stringent regulations and complex manufacturing processes for blood-derived products.
• Limited availability of plasma donors affecting product supply.

Market Report Coverage

The market report offers an in-depth analysis of the global intravenous immunoglobulins industry. It covers various parameters including market size, growth projections, trends, challenges, competitive landscape, and segmental insights. Additionally, the report provides regional breakdowns and strategic recommendations for key stakeholders.

Market Competitive Landscape

The IVIG market is moderately consolidated with the presence of several global players dominating regional and international markets. Companies are actively investing in research and development to expand their product portfolio and geographic footprint. Strategic mergers, acquisitions, and FDA approvals play a crucial role in maintaining competitiveness. For instance, Takeda’s acquisition of Shire expanded its footprint in immunoglobulin therapies, strengthening its market dominance.

Explore the full research report with detailed insights and TOC:https://www.fortunebusinessinsights.com/industry-reports/intravenous-immunoglobulins-market-100593 

Market Segments

The intravenous immunoglobulins market is segmented by application into:

• Primary Immunodeficiency
• Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
• Guillain-Barré Syndrome
• Myasthenia Gravis
• Immune Thrombocytopenic Purpura (ITP)
• Others

Market Regional Insights

North America currently dominates the IVIG market, owing to advanced healthcare systems, favorable reimbursement policies, and the high prevalence of immune disorders. The United States, in particular, holds a significant share due to its widespread use of immunoglobulin therapies in both approved and off-label indications.

Europe follows closely, with countries like Germany, France, and the U.K. leading adoption due to robust medical infrastructure and research initiatives.

Asia-Pacific is anticipated to exhibit the highest growth during the forecast period, driven by increasing healthcare expenditure, growing patient awareness, and rising demand for immunoglobulin treatments in emerging economies like India and China.

Future Market Scope

The future of the intravenous immunoglobulins market looks promising with innovations in plasma collection, product formulation, and administration methods. Key factors that will shape future growth include:

• Introduction of subcutaneous immunoglobulin (SCIG) alternatives that offer self-administration convenience.
• Improved diagnostic capabilities for rare immune disorders, increasing the target patient pool.
• Emerging opportunities in untapped markets through regulatory approvals and local production.
• Adoption of AI and machine learning for optimizing donor selection and plasma processing.

Despite certain challenges such as supply chain constraints and high costs, ongoing innovations and a proactive regulatory environment are likely to ensure long-term sustainability and growth in the IVIG market.

In conclusion, the global intravenous immunoglobulins market is undergoing dynamic changes, shaped by technological advancements, growing disease awareness, and expanding applications. Stakeholders who invest in R&D, strategic collaborations, and emerging markets are poised to benefit from sustained growth in this life-saving therapeutic sector.

About Us:
Fortune Business Insights provides expert corporate analysis and accurate data, enabling businesses of all sizes to make timely decisions. We offer customized solutions tailored to each client’s needs, helping them address unique challenges. Our goal is to empower clients with holistic market intelligence and offer granular insights into the market they operate in.

Our reports are a blend of quantitative and qualitative analysis, aimed at helping businesses achieve sustainable growth. Our experienced analysts and consultants use leading research methodologies to provide comprehensive market assessments enriched with relevant data.

At Fortune Business Insights, we aim to highlight growth opportunities for our clients, offering insights and recommendations that help them navigate technological and market changes. Our consulting services are designed to help companies uncover hidden opportunities and address competitive challenges.

Contact us:

Fortune Business Insights™ Pvt.

Phone: USA: +1 833 909 2966 (Toll-Free),

United Kingdom: +44 808 502 0280 (Toll-Free),

APAC: +91 744 740 1245

Email: [email protected]